Double-digit base business growth was achieved across all geographies, with strong new product launches and favorable forex, but results were impacted by semaglutide API issues and lower lenalidomide sales. Net cash surplus stood at ₹3,058 Cr, and ROCE was 5.3%.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.